Sharad H. Joshi Joins BioDirection, Inc. as President and CEO
Boston, MA – (PRNewswire) – BioDirection, Inc., a privately held medical device company developing cutting-edge and rapid point-of-care products for the diagnosis and management of concussions and other acquired traumatic brain injuries, today announced that Sharad H. Joshi has joined the company as President and Chief Executive Officer (CEO).
“Mr. Joshi is a proven, entrepreneurial medical device executive with a solid track record of driving global growth and laying strategic foundations for sustained success as CEO of multiple medical technology businesses,” said James Wylie, Executive Chairman of BioDirection. “His diverse background includes in-depth experience in research, product development, engineering, sales and marketing, global scaling of distribution channels, operations, quality and regulatory, partnerships and alliances.”
Prior to joining BioDirection, Mr. Joshi served as CEO for Bio-Chem Fluidics and President and CEO of Microline. He also co-founded Blue Torch Medical Technologies, Inc. and held multiple positions in product engineering, marketing and sales at Uromed, Inc. and Boston Scientific. Mr. Joshi holds an MSME, Mechanical Engineering and Pre-Med with a Biology minor from Northeastern University and an MBA, Entrepreneurship Studies from Babson College’s Olin School of Business.
“It is a pleasure to join BioDirection at this critical point of time in the commercialization of the Tbit™ System,” said Mr. Joshi. “Tbit is truly a disruptive biosensing nanowire technology with enormous potential to diagnose concussions as well as other traumatic brain conditions. My hands-on, collaborative management style and experience in growing and maximizing the potential of talent and innovative technology in the medical field is a direct match with BioDirection.”
About NanoDx, Inc.
NanoDx, Inc., is a privately held medical device company developing breakthrough, point-of-care diagnostic solutions that address unmet market needs and improve patient outcomes while reducing healthcare costs. The company's flagship product, the NanoDx™ System, is capable of detecting and quantifying biomarkers (analytes) from a small fluid specimen in less than 2 minutes. NanoDx's platform utilizes a proprietary nanosensor technology with a broad range of potential diagnostic applications including COVID-19, Traumatic Brain Injury (TBI), Influenza, Sepsis and Stroke. www.NanoDiagnostics.com